Abstract:Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used diabetes and obesity medications but have been associated with gastrointestinal (GI) adverse events. However, real-world evidence on comparative GI adverse reaction profiles is limited. Objectives: This study aimed to evaluate GI adverse events among GLP-1 RA users and compare semaglutide, dulaglutide, liraglutide, and exenatide safety regarding the GI adverse reaction profile. Methods: This retrospective cross-sectional analysis utilized real-world data on 10,328 adults with diabetes/obesity in the National Institutes of Health All of Us cohort. New GLP-1 RA users were identified, and GI adverse events were examined. Logistic regression determined factors associated with GI adverse events. Results: The mean age of the study population was 61.4 ± 12.6 years, 65.7% were female, 51.3% were White, and they had a high comorbidity burden. Abdominal pain (57.6%) was the most common GI adverse event, followed by constipation (30.4%), diarrhea (32.7%), nausea and vomiting (23.4%), GI bleeding (15.9%), gastroparesis (5.1%), and pancreatitis (3.4%). Dulaglutide and liraglutide had higher rates of abdominal pain, constipation, diarrhea, and nausea and vomiting than semaglutide and exenatide. Liraglutide and exenatide had the highest pancreatitis (4.0% and 3.8%, respectively). Compared to semaglutide, dulaglutide and liraglutide had higher odds of abdominal pain, and nausea and vomiting. They also had higher odds of gastroparesis than semaglutide. No significant differences existed in GI bleeding or pancreatitis risks between the GLP-1 RAs. Conclusions: In this real-world cohort, GI adverse events were common with GLP-1 RAs. Differences in GI safety profiles existed between agents, with exenatide appearing safer than other GLP-1 RAs, except for gastroparesis. These findings can inform GLP-1 RA selection considering GI risk factors. Further studies are needed to evaluate the causal relationship and GLP-1 RA safety with concomitant medication use.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate and compare different types of glucagon - like peptide - 1 receptor agonists (GLP - 1 RAs) in terms of gastrointestinal adverse events (GI adverse events) in the real world. Specifically, the study aims to: 1. **Evaluate gastrointestinal adverse events in GLP - 1 RA users**: Understand whether these drugs will cause common gastrointestinal problems in actual use, such as abdominal pain, constipation, diarrhea, nausea and vomiting, etc. 2. **Compare the safety of different GLP - 1 RAs**: In particular, the differences in gastrointestinal adverse reactions among four drugs, namely semaglutide, dulaglutide, liraglutide and exenatide. ### Research Background GLP - 1 RAs are a class of drugs used to treat type 2 diabetes mellitus (T2DM) and obesity. Due to their glucose - dependent mechanism, they can effectively improve blood - glucose control without significantly increasing the risk of hypoglycemia. However, these drugs are associated with gastrointestinal adverse events, and the safety differences among different drugs are not yet clear. Therefore, this study hopes to provide more accurate selection basis for clinicians by analyzing real - world data. ### Research Methods The study adopted the method of retrospective cross - sectional analysis and utilized the real - world data of the "All of Us" cohort of the National Institutes of Health (NIH). The study subjects included 10,328 adult patients newly using GLP - 1 RA, and factors related to gastrointestinal adverse events were determined by logistic regression analysis. ### Main Findings The study found that: - **The most common gastrointestinal adverse event was abdominal pain** (57.6%), followed by constipation (30.4%), diarrhea (32.7%), nausea and vomiting (23.4%). - **There are differences in the safety of different GLP - 1 RAs**: For example, the incidences of abdominal pain, constipation, diarrhea, nausea and vomiting in dulaglutide and liraglutide are higher than those in semaglutide and exenatide. - **Exenatide has the highest incidence in gastroparesis** (6.9%), while liraglutide and exenatide have higher incidences in pancreatitis (4.0% and 3.8% respectively). - **Male and older patients have a lower risk of gastrointestinal adverse events**, while the white race is associated with a higher risk of diarrhea and nausea and vomiting. ### Conclusion This study shows that in the real world, gastrointestinal adverse events of GLP - 1 RAs are relatively common, and there are safety differences among different drugs. These findings help clinicians select the most appropriate drugs according to patients' gastrointestinal risk factors and emphasize the importance of close monitoring of gastrointestinal adverse events. Further research is needed in the future to confirm these results and explore other potential influencing factors. ### Formula Summary The statistical analysis involved in this paper mainly uses the logistic regression model, and the formula is as follows: \[ \text{logit}(p) = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \cdots + \beta_n X_n \] where \( p \) is the probability of an event occurring, \( \beta_0 \) is the intercept term, \( \beta_i \) is the regression coefficient of each variable, and \( X_i \) is the independent variable. Through these analyses, researchers can quantify the influence of different factors on the incidence of gastrointestinal adverse events.

Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort

Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: a Systematic Review and Network Meta-Analysis.

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System

Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System

Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study

Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study

Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks

Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis

The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: a Mixed Treatment Comparison Meta-Analysis.

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists

Rates Of Repeat Egd In Non-Diabetic Adults With Glucagon-Like-Peptide- 1 Receptor Agonist Prescription: A Retrospective Matched Cohort Study

Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis

Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study

Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis

Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients